The experimental setting was the Leprdb/db mouse, a genetically obese animal that progressively develops the hallmarks of human type 2 diabetes: hyperglycemia, hyperinsulinemia, dyslipidemia, and systemic insulin resistance. Thirty diabetic mice were divided into a model group, a metformin group receiving 200 milligrams per kilogram per day, and three solanesol groups receiving 1, 5, or 15 milligrams per kilogram per day by oral gavage for 45 days. Six healthy C57BL/6J mice served as controls. Over the intervention window the team ran serial glucose tolerance and insulin tolerance tests, tracked fasting glucose weekly, and quantified a panel of serum and hepatic biochemical markers before dissecting liver, kidney, adipose depots, and fecal samples for molecular analysis.

The metabolic results were remarkable. By week six, medium-dose solanesol had reduced the insulin tolerance test area under the curve to 60.9 percent of untreated diabetic levels, marginally outperforming metformin’s 66.3 percent. Glycated serum protein, a marker of longer-term glucose exposure, fell to 74.8 to 78.4 percent of model values across all solanesol doses, mirroring metformin. Crucially, the homeostatic model assessment of insulin resistance dropped by roughly 84 percent in solanesol-treated animals versus 81.8 percent with metformin, while circulating insulin remained unchanged — evidence that the compound works by sensitizing tissues to insulin rather than by goading beta cells into secreting more of it. That non-secretagogue profile distinguishes solanesol from sulfonylureas and their well-known hypoglycemia risk.

Lipid outcomes were arguably even more impressive. High-dose solanesol drove low-density lipoprotein cholesterol down to 34.6 percent of diabetic levels, compared with only 62.3 percent under metformin, and cut triglycerides to roughly half of model values. White adipose tissue mass shrank significantly, brown adipose tissue expansion was curtailed, and the animals’ leptin-driven hyperphagia and polydipsia partially normalized. Histologically, the enlarged, pale, fat-infiltrated livers of diabetic mice regained near-normal architecture under medium and high-dose solanesol, with PAS staining revealing a threefold restoration of hepatic glycogen storage — a benefit metformin did not achieve. Masson’s trichrome staining confirmed the absence of fibrosis in all groups, pointing to a hepatoprotective rather than toxic profile even at the highest dose administered.

The pancreatic findings add a distinctive anti-inflammatory dimension. Solanesol suppressed interleukin-1 beta, the pivotal inflammasome-driven cytokine in islet inflammation, by 37 to 42 percent across doses, exceeding metformin’s 30 percent reduction, while leaving TNF-alpha, IL-6, and IL-10 untouched. This pinpoint suppression occurred alongside preserved C-peptide and insulin secretion, suggesting the compound shields beta cells from inflammatory stress without disturbing their secretory machinery. In the kidney, solanesol delivered an unexpected bonus: serum uric acid fell to 65 to 70 percent of diabetic levels, an effect achieved independently of hepatic xanthine oxidase and therefore likely involving reprogramming of renal urate transporters. Because 17 to 22 percent of diabetic patients suffer comorbid gout, and metformin’s own uric acid profile was neutral to slightly adverse, this anti-hyperuricemic activity could prove clinically significant.

To uncover mechanism, the team sequenced the hepatic transcriptome, generating 82.63 gigabases of high-quality data, and profiled the liver proteome by 4D label-free quantification on a timsTOF Pro2 mass spectrometer. Differential expression analysis revealed thousands of genes dysregulated in diabetic livers, with a conspicuous cluster of 31 oxidative phosphorylation-related genes overexpressed in disease. Network analysis identified hub nodes concentrated in respiratory chain complexes I, III, IV, and V — including Ndufa5, Cox6b1, Atp5h, and Uqcrb — and solanesol treatment normalized this pathological signature. Enzyme assays told the deeper story: although respiratory chain gene expression was elevated in diabetic mice, actual complex activity was reduced, an apparently futile compensatory response that drives ATP depletion and reactive oxygen species generation. Solanesol reversed the functional impairment, restoring electron transport across complexes I through V, a coordinated rebalancing that contrasts with metformin’s singular inhibition of complex I.

The proteomic and qPCR data converged on a second mechanistic axis: lipid metabolic reprogramming. Six core regulators — Apoa4, Acaca, Acly, Fasn, Abca1, and Fabp5 — showed concordant changes across transcriptomic and protein platforms. Solanesol suppressed the Acly-Acaca-Fasn cascade that drives de novo lipogenesis, blocking the conversion of citrate to acetyl-CoA and onward to fatty acids, while simultaneously upregulating Abca1 to promote cholesterol efflux and Fabp5 to channel fatty acids into mitochondrial beta-oxidation. Reduced free fatty acid flux then relieved the abnormal PPAR-delta elevation seen in diabetic livers, tempering inflammation. The authors link Abca1 activation to JAK2-STAT3 signaling in macrophages that restrains NF-kappa-B-driven cytokine release, a dual metabolic-immune effect observed in islets and skeletal muscle as well as liver.

Perhaps the most systems-level findings came from the gut. Sequencing of the V3-V4 region of the bacterial 16S rRNA gene from 1.48 million high-quality sequences showed that solanesol restructured the diabetic microbiome, enriching beneficial taxa such as Alistipes and Anaerotruncus, known short-chain fatty acid producers, along with Odoribacteraceae and Parasutterella, implicated in bile acid metabolism and PPAR signaling. Fecal metabolomics by LC-MS/MS identified 97 disease-elevated metabolites that solanesol normalized, mapping onto bile acid biosynthesis, taurine metabolism, and steroid hormone pathways, while restoring 43 depleted metabolites tied to alpha-linolenic acid metabolism and oxidative phosphorylation. Quantitative fatty acid profiling revealed a chain-length-dependent pattern: fecal short-chain fatty acids fell further under treatment, consistent with enhanced intestinal absorption of these beneficial molecules, medium-chain fatty acids normalized, and long-chain fatty acids rebounded toward healthy levels, including rises in palmitoleate, gamma-linolenate, and eicosatrienoate — lipids connected to gut-liver and gut-brain signaling.

Those neuroactive lipid shifts resonate with prior work showing solanesol’s neuroprotection in models of Huntington’s disease, autism spectrum disorder, cerebral hemorrhage, and bipolar disorder, effects attributed to mitochondrial restoration and SIRT-1 activation. The new data also reposition the molecule relative to coenzyme Q10 itself. Solanesol significantly elevated ubiquinone-1, a CoQ10 precursor, yet conventional CoQ10 supplementation suffers from oral bioavailability below 5 percent and has failed to improve glycemic control in meta-analyses of diabetic patients. Solanesol appears to bypass those pharmacokinetic limitations, prompting the authors to propose a precursor-to-therapeutic repositioning strategy in which the intermediate outperforms the end product it was once merely used to synthesize.

The authors are candid about limitations: the six-mice-per-group design and the roughly seven-week intervention cannot capture subtle trends or long-term complication prevention, and they call for extended studies of six months or more, diverse disease models, and eventual clinical evaluation. Still, the breadth of benefit — hepatic steatosis reduced by about 59 percent, pancreatic IL-1beta by about 42 percent, serum uric acid by about 45 percent, plus microbiome and metabolome remodeling — achieved at 5 milligrams per kilogram per day, marks solanesol as a rare multi-target natural modulator of what the team calls the metabolic quartet: dysglycemia, dyslipidemia, hyperuricemia, and multi-organ inflammation. If those effects translate beyond rodents, a molecule extracted from tobacco waste streams could become an unexpected weapon against one of the world’s fastest-growing pandemics.

Subject of Research: Multi-organ protective mechanisms of the plant compound solanesol against insulin resistance in type 2 diabetic mice, revealed through integrated multi-omics analysis.

Article Title: Integrated multi-omics unravels solanesol’s multi-organ protection mechanisms against insulin resistance in type 2 diabetic mice

Article References: Zhang, W., Cheng, W., Fu, J., Zeng, R., Wang, Z., Zhou, J., Chen, Y., & Zhang, W. (2026). Integrated multi-omics unravels solanesol’s multi-organ protection mechanisms against insulin resistance in type 2 diabetic mice. Journal of Advanced Research, 87, 1011-1026. https://doi.org/10.1016/j.jare.2025.12.025

Image Credits: AI Generated

DOI: 10.1016/j.jare.2025.12.025

Keywords: solanesol, type 2 diabetes, insulin resistance, metformin, multi-omics, mitochondria, oxidative phosphorylation, gut microbiome, fatty liver, hyperuricemia, db/db mice, natural products

Tofogliflozin, a member of the SGLT2 inhibitor class of medications, has garnered attention for its potential renal protective effects. These advantages stem from its unique mechanism of action, which involves the prevention of glucose reabsorption in the kidneys, thus promoting glycosuria and subsequently leading to osmotic diuresis. This process not only aids in blood sugar control but also has been shown to reduce hyperfiltration in diabetic patients, a key factor in the progression of kidney damage.

The TRUTH-DKD trial is particularly noteworthy, as it is one of the first large-scale, randomized studies to directly compare Tofogliflozin with Metformin, a longstanding cornerstone in the pharmacological management of type 2 diabetes. While Metformin primarily works by decreasing hepatic glucose output and enhancing insulin sensitivity, its efficacy in preventing kidney disease progression has been less pronounced compared to the emerging data on SGLT2 inhibitors. This trial is poised to clarify the renal advantages of Tofogliflozin and could potentially reshape therapeutic strategies for individuals suffering from both diabetes and kidney impairments.

A primary endpoint of the study is the alteration in the urinary albumin-to-creatinine ratio, which serves as a crucial biomarker for kidney function and disease progression. Elevated levels of albumin in the urine are indicative of glomerular damage, and reducing these levels is vital in mitigating long-term renal complications. The trial’s design includes carefully defined inclusion and exclusion criteria to ensure that the findings are representative of the broader diabetic population, thereby enhancing the applicability of the results.

Moreover, the researchers are committed to investigating not only the effectiveness of Tofogliflozin in comparison to Metformin but also the safety profiles associated with each medication. The trial intends to monitor adverse events meticulously, providing comprehensive insights into the tolerability of both drugs in a diabetic population at risk for kidney disease. This focus on safety is paramount, particularly given the increasing emphasis on personalized medicine and understanding individual response to treatment.

Another critical aspect of the TRUTH-DKD trial is its commitment to addressing racial and ethnic disparities in diabetic kidney disease management. Historically, certain populations have been underrepresented in clinical trials, leading to gaps in understanding how different demographics respond to therapies. By aiming for a diverse participant pool, the TRUTH-DKD study aims to provide more generalized findings applicable to a range of patients across various backgrounds.

As the study unfolds, it leverages a robust methodology that encompasses patient-centered outcomes. Researchers will not only look at clinical markers but will also consider factors that impact the quality of life for individuals living with diabetes. This holistic approach ensures that the trial results will inform clinical practice guidelines beyond mere efficacy, reinforcing the importance of quality of life as a critical endpoint in treatment evaluation.

The significance of this trial extends beyond immediate therapeutic outcomes; it represents a crucial step in understanding the long-term implications of medication choices in diabetic patients. When managing diabetes, healthcare providers must consider not only glucose control but also the preservation of kidney function, which is often intertwined with cardiovascular health as well. Therefore, findings from this trial could have far-reaching effects on comprehensive diabetes management.

In recent years, the exploration of diabetes treatments has highlighted the importance of addressing comorbid conditions prevalent among diabetic patients. Given the intertwining nature of diabetes and chronic kidney disease, the TRUTH-DKD trial aligns with the growing recognition that multi-faceted approaches addressing various health issues concurrently can yield better patient outcomes. This perspective of integrated care is becoming increasingly vital in chronic disease management.

As discussions around health equity evolve, the outcomes of this trial will ideally advocate for updated clinical practice standards that prioritize access to effective treatment options like Tofogliflozin for individuals at high risk for kidney disease. The potential benefits include not only improved clinical outcomes but also a decrease in healthcare costs associated with advanced disease management and treatment.

Ultimately, the TRUTH-DKD trial’s findings have the potential to establish new benchmarks in diabetic kidney disease treatment. Should Tofogliflozin demonstrate superior efficacy compared to Metformin in reducing urinary albumin-to-creatinine ratios, clinical guidelines may shift, recommending SGLT2 inhibitors as preferred first-line therapies for patients with diabetes and kidney concerns. This could lead to broader adoption of SGLT2 inhibitors in clinical settings.

As the world continues to face a diabetes epidemic, trials like TRUTH-DKD are essential. They pave the way for innovative solutions, informed practice, and hopefully a brighter prognosis for individuals struggling with the dual challenges of diabetes and kidney disease. By advancing our understanding of these interconnected health issues, researchers can help ensure that the management of diabetes not only focuses on glucose control but also prioritizes kidney health and the overall well-being of patients.

The impact of such studies cannot be understated as they contribute to the evolving landscape of diabetes management. As physicians await the trial’s outcome, there’s growing optimism surrounding the potential therapeutic shifts that could arise from proof of Tofogliflozin’s benefits over Metformin. The future of diabetes care may ultimately hinge upon the effective integration of new treatments backed by comprehensive clinical evidence.

As the TRUTH-DKD trial progresses, it represents a significant stride in diabetes care, addressing the urgent need for effective, long-term management strategies for diabetic kidney disease. The collaboration among researchers, healthcare providers, and patients is crucial to translating this research into actionable clinical practice, ensuring that the voices of individuals facing diabetes-related challenges are heard and valued in the quest for better healthcare solutions.

Subject of Research: Effect of Tofogliflozin on Urinary Albumin-to-Creatinine Ratio in Diabetic Kidney Disease

Article Title: Effect of Tofogliflozin on Urinary Albumin-to-Creatinine Ratio vs. Metformin in Diabetic Kidney Disease: Rationale and Study Protocol of the TRUTH-DKD Trial

Article References:

Kimura, K., Takagi, Y., Harada, M. et al. Effect of Tofogliflozin on Urinary Albumin-to-Creatinine Ratio vs. Metformin in Diabetic Kidney Disease: Rationale and Study Protocol of the TRUTH-DKD Trial. Diabetes Ther (2025). https://doi.org/10.1007/s13300-025-01822-8

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s13300-025-01822-8

Keywords: Diabetic Kidney Disease, Tofogliflozin, Metformin, Urinary Albumin-to-Creatinine Ratio, TRUTH-DKD Trial.